“T-body” or chimeric antigen receptor (CAR) technology, which combines the specificity of an antibody with the homing, tissue penetration, and target cell destruction of T cells, was first described in 1993. After many years of unmet promise, significant improvements in gene transfer, including the development of efficient retroviral vectors for transduction of human T cells, and better understanding of immunological pathways and immune cell interactions, are allowing this technology to reach a critical phase of evaluation, in which we will learn whether the approach can truly meet expectations. In this review we summarize the concept of CAR-based immunotherapy, describe the steps accomplished, and outline the future progress we need to make if this approach is truly to improve cancer immunotherapy.
Get full access to this article
View all access options for this article.
References
1.
AhmadzadehM., RosenbergS.A.2006. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood, 107:2409–2414.
2.
AhmedN., RatnayakeM., SavoldoB., PerlakyL., DottiG., WelsW.S., BhattacharjeeM.B., GilbertsonR.J., ShineH.D., WeissH.L., RooneyC.M., HeslopH.E., GottschalkS.2007. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res., 67:5957–5964.
3.
AlpdoganO., MuriglanS.J., EngJ.M., WillisL.M., GreenbergA.S., KappelB.J., van den BrinkM.R.2003. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest., 112:1095–1107.
4.
AndorskyD.J., TimmermanJ.M.2008. Interleukin-21: Biology and application to cancer therapy. Expert Opin. Biol. Ther., 8:1295–1307.
5.
BergerC., JensenM.C., LansdorpP.M., GoughM., ElliottC., RiddellS.R.2008. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest., 118:294–305.
6.
BergerC., BergerM., HackmanR.C., GoughM., ElliottC., JensenM.C., RiddellS.R.2009. Safety and immunological effects of IL-15 administration in nonhuman primates. Blood2009 Jul 15 [Epub ahead of print].
7.
BoesteanuA.C., KatsikisP.D.2009. Memory T cells need CD28 costimulation to remember. Semin. Immunol., 21:69–77.
BollardC.M., AguilarL., StraathofK.C., GahnB., HulsM.H., RousseauA., SixbeyJ., GresikM.V., CarrumG., HudsonM., DillooD., GeeA., BrennerM.K., RooneyC.M., HeslopH.E.2004. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med., 200:1623–1633.
10.
BoniniC., FerrariG., VerzelettiS., ServidaP., ZapponeE., RuggieriL., PonzoniM., RossiniS., MavilioF., TraversariC., BordignonC.1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276:1719–1724.
BordignonC., NotarangeloL.D., NobiliN., FerrariG., CasoratiG., PaninaP., MazzolariE., MaggioniD., RossiC., ServidaP., UgazioA.G., MavilioF.1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science, 270:470–475.
13.
BrennerM.K., HeslopH.E.2003. Is retroviral gene marking too dangerous to use?Cytotherapy, 5:190–193.
14.
BrentjensR., RiviereI., HollymanD., TaylorC., NikhaminY., StefanskiJ., LeeJ., YehR., SantosE., SadelainM.2009. Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with bulky CLL [abstract]Mol. Ther., 17,Suppl. 12009.
15.
CavalieriS., CazzanigaS., GeunaM., MagnaniZ., BordignonC., NaldiniL., BoniniC.2003. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood, 102:497–505.
16.
ComoliP., PedrazzoliP., MaccarioR., BassoS., CarminatiO., LabirioM., SchiavoR., SecondinoS., FrassonC., PerottiC., MoroniM., LocatelliF., SienaS.2005. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol., 23:8942–8949.
17.
CooperL.J., ToppM.S., SerranoL.M., GonzalezS., ChangW.C., NaranjoA., WrightC., PopplewellL., RaubitschekA., FormanS.J., JensenM.C.2003. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101:1637–1644.
18.
CooperM.A., FehnigerT.A., TurnerS.C., ChenK.S., GhaheriB.A., GhayurT., CarsonW.E., CaligiuriM.A.2001. Human natural killer cells: A unique innate immunoregulatory role for the CD56bright subset. Blood, 97:3146–3151.
19.
DieliF., VermijlenD., FulfaroF., CaccamoN., MeravigliaS., CiceroG., RobertsA., BuccheriS., D'AsaroM., GebbiaN., SalernoA., EberlM., HaydayA.C.2007. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res., 67:7450–7457.
20.
Di StasiA., De AngelisB., RooneyC.M., ZhangL., MahendravadaA., FosterA.E., HeslopH.E., BrennerM.K., DottiG., SavoldoB.2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 113:6392–6402.
21.
DottiG., SavoldoB., PuleM., StraathofK.C., BiagiE., YvonE., VigourouxS., BrennerM.K., RooneyC.M.2005. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood, 105:4677–4684.
22.
DudleyM.E., RosenbergS.A.2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer, 3:666–675.
23.
DudleyM.E., WunderlichJ.R., YangJ.C., SherryR.M., TopalianS.L., RestifoN.P., RoyalR.E., KammulaU., WhiteD.E., MavroukakisS.A., RogersL.J., GraciaG.J., JonesS.A., MangiameliD.P., PelletierM.M., Gea-BanaclocheJ., RobinsonM.R., BermanD.M., FilieA.C., AbatiA., RosenbergS.A.2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23:2346–2357.
24.
DudleyM.E., YangJ.C., SherryR., HughesM.S., RoyalR., KammulaU., RobbinsP.F., HuangJ., CitrinD.E., LeitmanS.F., WunderlichJ., RestifoN.P., ThomasianA., DowneyS.G., SmithF.O., KlapperJ., MortonK., LaurencotC., WhiteD.E., RosenbergS.A.2008. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol., 26:5233–5239.
25.
DuraiswamyJ., BurrowsJ.M., BharadwajM., BurrowsS.R., CooperL., PimtanothaiN., KhannaR.2003. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J. Virol., 77:7401–7410.
26.
EshharZ., WaksT., GrossG., SchindlerD.G.1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U.S.A., 90:720–724.
27.
FinneyH.M., LawsonA.D., BebbingtonC.R., WeirA.N.1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol., 161:2791–2797.
28.
GattinoniL., FinkelsteinS.E., KlebanoffC.A., AntonyP.A., PalmerD.C., SpiessP.J., HwangL.N., YuZ., WrzesinskiC., HeimannD.M., SurhC.D., RosenbergS.A., RestifoN.P.2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med., 202:907–912.
29.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., Le DeistF., WulffraatN., McIntyreE., RadfordI., VillevalJ.L., FraserC.C., Cavazzana-CalvoM., FischerA.2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348:255–256.
HeslopH.E., NgC.Y., LiC., SmithC.A., LoftinS.K., KranceR.A., BrennerM.K., RooneyC.M.1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2:551–555.
32.
HombachA., HeuserC., SircarR., TillmannT., DiehlV., PohlC., AbkenH.1999. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J. Immunother., 22:473–480.
33.
HuW.S., PathakV.K.2000. Design of retroviral vectors and helper cells for gene therapy. Pharmacol. Rev., 52:493–511.
34.
HuangX., GuoH., KangJ., ChoiS., ZhouT.C., TammanaS., LeesC.J., LiZ.Z., MiloneM., LevineB.L., TolarJ., JuneC.H., ScottM.R., WagnerJ.E., BlazarB.R., ZhouX.2008. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol. Ther., 16:580–589.
ImaiC., IwamotoS., CampanaD.2005. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood, 106:376–383.
37.
JensenM.C., CooperL.J., WuA.M., FormanS.J., RaubitschekA.2003. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy, 5:131–138.
38.
KaechS.M., TanJ.T., WherryE.J., KoniecznyB.T., SurhC.D., AhmedR.2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol., 4:1191–1198.
39.
KershawM.H., WangG., WestwoodJ.A., PachynskiR.K., TiffanyH.L., MarincolaF.M., WangE., YoungH.A., MurphyP.M., HwuP.2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther., 13:1971–1980.
40.
KershawM.H., WestwoodJ.A., ParkerL.L., WangG., EshharZ., MavroukakisS.A., WhiteD.E., WunderlichJ.R., CanevariS., Rogers-FreezerL., ChenC.C., YangJ.C., RosenbergS.A., HwuP.2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 12:6106–6115.
41.
KimH., PengG., HicksJ.M., WeissH.L., Van MeirE.G., BrennerM.K., YotndaP.2008. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol. Ther., 16:599–606.
42.
KowolikC.M., ToppM.S., GonzalezS., PfeifferT., OlivaresS., GonzalezN., SmithD.D., FormanS.J., JensenM.C., CooperL.J.2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res., 66:10995–11004.
43.
LamersC.H., SleijferS., VultoA.G., KruitW.H., KliffenM., DebetsR., GratamaJ.W., StoterG., OosterwijkE.2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J. Clin. Oncol., 24:e20–e22.
LiuK., RosenbergS.A.2001. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol., 167:6356–6365.
46.
LoskogA., GiandomenicoV., RossigC., PuleM., DottiG., BrennerM.K.2006. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia, 20:1819–1828.
47.
MaA., KokaR., BurkettP.2006. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol., 24:657–679.
48.
MaherJ., BrentjensR.J., GunsetG., RiviereI., SadelainM.2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol., 20:70–75.
49.
MillerD.G., AdamM.A., MillerA.D.1990. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol., 10:4239–4242.
50.
MiloneM.C., FishJ.D., CarpenitoC., CarrollR.G., BinderG.K., TeacheyD., SamantaM., LakhalM., GlossB., net-DesnoyersG., CampanaD., RileyJ.L., GruppS.A., JuneC.H.2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther., 17:1453–1464.
51.
MitchellD.A., KarikariI., CuiX., XieW., SchmittlingR., SampsonJ.H.2008. Selective modification of antigen-specific T cells by RNA electroporation. Hum. Gene Ther., 19:511–521.
52.
MitsuyasuR.T., AntonP.A., DeeksS.G., ScaddenD.T., ConnickE., DownsM.T., BakkerA., RobertsM.R., JuneC.H., JalaliS., LinA.A., Pennathur-DasR., HegeK.M.2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood, 96:785–793.
53.
MontiniE., CesanaD., SchmidtM., SanvitoF., PonzoniM., BartholomaeC., SergiS.L., BenedicentiF., AmbrosiA., Di SerioC., DoglioniC., Von KalleC., NaldiniL.2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol., 24:687–696.
54.
MorganR.A., DudleyM.E., WunderlichJ.R., HughesM.S., YangJ.C., SherryR.M., RoyalR.E., TopalianS.L., KammulaU.S., RestifoN.P., ZhengZ., NahviA., de VriesC.R., Rogers-FreezerL.J., MavroukakisS.A., RosenbergS.A.2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126–129.
55.
NaldiniL., BlomerU., GallayP., OryD., MulliganR., GageF.H., VermaI.M., TronoD.1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272:263–267.
56.
NanjappaS.G., WalentJ.H., MorreM., SureshM.2008. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J. Clin. Invest., 118:1027–1039.
57.
NannoM., ShioharaT., YamamotoH., KawakamiK., IshikawaH.2007. γδ T cells: Firefighters or fire boosters in the front lines of inflammatory responses. Immunol. Rev., 215:103–113.
58.
ParkJ.R., DigiustoD.L., SlovakM., WrightC., NaranjoA., WagnerJ., MeechoovetH.B., BautistaC., ChangW.C., OstbergJ.R., JensenM.C.2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther., 15:825–833.
59.
PaulosC.M., SuhoskiM.M., PlesaG., JiangT., BasuS., GolovinaT.N., JiangS., AquiN.A., PowellD.J.Jr., LevineB.L., CarrollR.G., RileyJ.L., JuneC.H.2008. Adoptive immunotherapy: Good habits instilled at youth have long-term benefits. Immunol. Res., 42:182–196.
60.
PoppemaS., PottersM., VisserL., van den BergA.M.1998. Immune escape mechanisms in Hodgkin's disease. Ann. Oncol., 9,Suppl. 5:S21–S24.
61.
PowellD.J.Jr., DudleyM.E., RobbinsP.F., RosenbergS.A.2005. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood, 105:241–250.
62.
PuleM.A., StraathofK.C., DottiG., HeslopH.E., RooneyC.M., BrennerM.K.2005. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther., 12:933–941.
63.
PuleM.A., SavoldoB., MyersG.D., RossigC., RussellH.V., DottiG., HulsM.H., LiuE., GeeA.P., MeiZ., YvonE., WeissH.L., LiuH., RooneyC.M., HeslopH.E., BrennerM.K.2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14:1264–1270.
64.
QuintarelliC., VeraJ.F., SavoldoB., Giordano AttianeseG.M., PuleM., FosterA.E., HeslopH.E., RooneyC.M., BrennerM.K., DottiG.2007. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood, 110:2793–2802.
65.
RischerM., PschererS., DuweS., VormoorJ., JurgensH., RossigC.2004. Human γδ T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br. J. Haematol., 126:583–592.
66.
RobbinsP.F., DudleyM.E., WunderlichJ., El-GamilM., LiY.F., ZhouJ., HuangJ., PowellD.J.Jr., RosenbergS.A.2004. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol., 173:7125–7130.
67.
RooneyC.M., SmithC.A., NgC.Y., LoftinS., LiC., KranceR.A., BrennerM.K., HeslopH.E.1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345:9–13.
68.
RooneyC.M., SmithC.A., NgC.Y., LoftinS.K., SixbeyJ.W., GanY., SrivastavaD.K., BowmanL.C., KranceR.A., BrennerM.K., HeslopH.E.1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92:1549–1555.
69.
RosenbergS.A., AebersoldP., CornettaK., KasidA., MorganR.A., MoenR., KarsonE.M., LotzeM.T., YangJ.C., TopalianS.L., MerinoM.J., CulverK., MillerA.D., BlaeseR.M., AndersonW.F.1990. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323:570–578.
70.
RosenbergS.A., YannelliJ.R., YangJ.C., TopalianS.L., SchwartzentruberD.J., WeberJ.S., ParkinsonD.R., SeippC.A., EinhornJ.H., WhiteD.E.1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst., 86:1159–1166.
71.
RosenbergS.A., SportesC., AhmadzadehM., FryT.J., NgoL.T., SchwarzS.L., Stetler-StevensonM., MortonK.E., MavroukakisS.A., MorreM., BuffetR., MackallC.L., GressR.E.2006. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother., 29:313–319.
72.
RosenbergS.A., RestifoN.P., YangJ.C., MorganR.A., DudleyM.E.2008. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 8:299–308.
73.
RossigC., BollardC.M., NuchternJ.G., MerchantD.A., BrennerM.K.2001. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer, 94:228–236.
74.
RossigC., BollardC.M., NuchternJ.G., RooneyCM, BrennerMK. 2002. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 99:2009–2016.
SadelainM., BrentjensR., RiviereI.2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol., 21:215–223.
77.
SavoldoB., RooneyC.M., Di StasiA., AbkenH., HombachA., FosterA.E., ZhangL., HeslopH.E., BrennerM.K., DottiG.2007. Epstein-Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood, 110:2620–2630.
78.
SchlunsK.S., KieperW.C., JamesonS.C., LefrancoisL.2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol., 1:426–432.
79.
SinghH., ManuriP.R., OlivaresS., DaraN., DawsonM.J., HulsH., HackettP.B., KohnD.B., ShpallE.J., ChamplinR.E., CooperL.J.2008. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res., 68:2961–2971.
80.
SportesC., HakimF.T., MemonS.A., ZhangH., ChuaK.S., BrownM.R., FleisherT.A., KrumlaufM.C., BabbR.R., ChowC.K., FryT.J., EngelsJ., BuffetR., MorreM., AmatoR.J., VenzonD.J., KorngoldR., PecoraA., GressR.E., MackallC.L.2008. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med., 205:1701–1714.
81.
StastnyM.J., BrownC.E., RuelC., JensenM.C.2007. Medulloblastomas expressing IL13Rα2 are targets for IL13-zetakine+ cytolytic T cells. J. Pediatr. Hematol. Oncol., 29:669–677.
82.
StraathofK.C., BollardC.M., PopatU., HulsM.H., LopezT., MorrissM.C., GresikM.V., GeeA.P., RussellH.V., BrennerM.K., RooneyC.M., HeslopH.E.2005a. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood, 105:1898–1904.
83.
StraathofK.C., PuleM.A., YotndaP., DottiG., VaninE.F., BrennerM.K., HeslopH.E., SpencerD.M., RooneyC.M.2005b. An inducible caspase 9 safety switch for T-cell therapy. Blood, 105:4247–4254.
84.
TillB.G., JensenM.C., WangJ., ChenE.Y., WoodB.L., GreismanH.A., QianX., JamesS.E., RaubitschekA., FormanS.J., GopalA.K., PagelJ.M., LindgrenC.G., GreenbergP.D., RiddellS.R., PressO.W.2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 112:2261–2271.
85.
VeraJ., SavoldoB., VigourouxS., BiagiE., PuleM., RossigC., WuJ., HeslopH.E., RooneyC.M., BrennerM.K., DottiG.2006. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 108:3890–3897.
86.
VeraJ.F., HoyosV., SavoldoB., QuintarelliC., Giordano AttianeseG.M., LeenA.M., LiuH., FosterA.E., HeslopH.E., RooneyC.M., BrennerM.K., DottiG.2009. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther., 17:880–888.
87.
WalkerR.E., BechtelC.M., NatarajanV., BaselerM., HegeK.M., MetcalfJ.A., StevensR., HazenA., BlaeseR.M., ChenC.C., LeitmanS.F., PalenskyJ., WittesJ., DaveyR.T.Jr., FalloonJ., PolisM.A., KovacsJ.A., BroadD.F., LevineB.L., RobertsM.R., MasurH., LaneH.C.2000. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood, 96:467–474.
88.
WilsonM.H., CoatesC.J., GeorgeA.L.Jr.2007. PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther., 15:139–145.
89.
YeeC., ThompsonJ.A., ByrdD., RiddellS.R., RocheP., CelisE., GreenbergP.D.2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A., 99:16168–16173.
90.
ZouW.2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 5:263–274.
